» Articles » PMID: 34441386

PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain

Overview
Specialty Radiology
Date 2021 Aug 27
PMID 34441386
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Anti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC analyzed in our center between 2017 and 2020, as well as to correlate the expression values of the same patient in different tested samples. PD-L1 immunohistochemistry (IHC) was carried out on 1279 external and internal samples: 482 negative (tumor proportion score, TPS < 1%; 37.7%), 444 low-expression (TPS 1-49%; 34.7%) and 353 high-expression (TPS ≥ 50%; 27.6%). Similar results were observed with samples from our institution (N = 816). Significant differences were observed with respect to tumor histological type ( = 0.004); squamous carcinoma was positive in a higher proportion of cases than other histological types. There were also differences between PD-L1 expression and the type of sample analyzed (surgical, biopsy, cytology; < 0.001), with a higher frequency of negative cytology. In addition, there were cases with more than one PD-L1 determination, showing heterogeneity. Our results show strong correlation with the literature data and reveal heterogeneity between tumors and samples from the same patient, which could affect eligibility for treatment with immunotherapy.

Citing Articles

Surgical Treatment Outcomes of Patients with Non-Small Cell Lung Cancer and Lymph Node Metastases.

Shimizu Y, Koike T, Hasebe T, Nakamura M, Goto T, Toyabe S Cancers (Basel). 2023; 15(12).

PMID: 37370708 PMC: 10296079. DOI: 10.3390/cancers15123098.


Clinicopathological Features and Status of Programmed Death Ligand-1 (PD-L1) Expression in Lung Cancer: A Single Centre Study From North India.

Ganie F, Mehfooz N, Siraj F, Khan U, Mantoo S, Dhar A Cureus. 2023; 15(2):e35056.

PMID: 36942175 PMC: 10024510. DOI: 10.7759/cureus.35056.


Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer.

Fu F, Deng C, Sun W, Zheng Q, Jin Y, Li Y Respir Res. 2022; 23(1):302.

PMID: 36335353 PMC: 9636784. DOI: 10.1186/s12931-022-02201-8.


Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.

Maule J, Clinton L, Graf R, Xiao J, Oxnard G, Ross J J Immunother Cancer. 2022; 10(10).

PMID: 36302564 PMC: 9621188. DOI: 10.1136/jitc-2022-005573.

References
1.
Rodriguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E . Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021; 32(7):881-895. DOI: 10.1016/j.annonc.2021.04.008. View

2.
Gosney J, Boothman A, Ratcliffe M, Kerr K . Cytology for PD-L1 testing: A systematic review. Lung Cancer. 2020; 141:101-106. DOI: 10.1016/j.lungcan.2020.01.010. View

3.
Reck M, Mok T, Nishio M, Jotte R, Cappuzzo F, Orlandi F . Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019; 7(5):387-401. DOI: 10.1016/S2213-2600(19)30084-0. View

4.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

5.
Kim S, Koh J, Kwon D, Keam B, Go H, Kim Y . Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. Eur J Cancer. 2017; 75:141-149. DOI: 10.1016/j.ejca.2017.01.004. View